Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma.

Ther Adv Med Oncol · 2021 · PMC8450613 · PMID 34552668

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

an obvious trendp = 0.07so close (0.05 < p ≤ 0.1)

No statistically significant difference in survival was seen; however, the authors seemed to disregard an obvious trend towards improved survival with neoadjuvant FOLFIRINOX compared to gemcitabine/nab-paclitaxel [HR = 1.48, 95% confidence interval (CI) 0.97–2.26, p = 0.07].

also in 1,006 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.